{"filings":[{"id":2033156,"accession_number":"0000031791-26-000022","cik":31791,"company_name":"REVVITY, INC.","ticker":"RVTY","form_type":"8-K","filed_at":"2026-08-04T10:20:40+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Revvity Q2 adjusted EPS $1.41 beats prior year; divests China IDX for up to $200M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $730M (+1.4% reported); GAAP EPS $0.48; adjusted EPS $1.41 (+19% YoY).","Pro forma revenue $711M (+4% YoY); pro forma adjusted EPS $1.41 (+23% YoY).","Adjusted operating margin 28.9% (up 230bps); includes $16M tariff refunds.","Divests China IDX for up to $200M; expected close by end of 2027; represented ~6% of FY2025 revenue.","Raises full-year guidance (pro forma basis); no specific figures provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":10797870952.86337,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97948,"accession_number":"0000031791-26-000016","cik":31791,"company_name":"REVVITY, INC.","ticker":"RVTY","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Revvity Q1 adj EPS $1.06 beats $1.01 YoY; revenue $711M +7%; plans China IDX divestiture","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 GAAP EPS $0.37 vs $0.35 YoY; adjusted EPS $1.06 vs $1.01; revenue $711M (+7% YoY).","Pro forma (ex-China IDX) revenue $687M, adj EPS $1.04 vs $0.95 YoY.","Signed LOI to sell China Immunodiagnostics business for up to $200M; expects close by 2027.","China IDX represented ~6% of FY2025 total revenue; definitive agreement expected Q2 2026.","Full-year 2026 guidance updated on pro forma basis; management to discuss on call."],"consensus_eps_estimate":null,"consensus_eps_actual":0.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":711118000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":10797870952.86337,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97947,"accession_number":"0001193125-26-201401","cik":31791,"company_name":"REVVITY, INC.","ticker":"RVTY","form_type":"8-K","filed_at":"2026-05-01T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Revvity shareholders approve bylaw amendment allowing 25% owners to call special meetings; all director nominees elected","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Shareholders approved bylaw amendment allowing 25% owners to call special meetings (99,086,661 for, 440,300 against).","All ten director nominees elected; Peter Barrett received lowest support (93,823,710 for, 5,674,907 against).","Ratified Deloitte & Touche as independent auditor (102,992,151 for, 1,036,994 against).","Advisory say-on-pay approved (94,377,138 for, 3,770,364 against).","Shareholder proposal requiring executive stock ownership rejected (22,974,850 for, 76,502,157 against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":10797870952.86337,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":113162,"accession_number":"0000031791-26-000007","cik":31791,"company_name":"REVVITY, INC.","ticker":"RVTY","form_type":"8-K","filed_at":"2026-02-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Revvity Q4 revenue $772M (+6% YoY), adj EPS $1.70 vs $1.42; initiates 2026 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 GAAP EPS $0.87 vs $0.78; adjusted EPS from cont. ops. $1.70 vs $1.42.","Full year 2025 revenue $2,856M (+3.7% YoY); GAAP EPS $2.07 vs $2.20; adj. EPS $5.06 vs $4.90.","Q4 organic revenue growth 4%; adj. operating margin 29.7% vs 30.3%.","Company initiates full year 2026 guidance; no specific numbers provided in release."],"consensus_eps_estimate":null,"consensus_eps_actual":2.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":2856051000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":10797870952.86337,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":113161,"accession_number":"0000031791-26-000003","cik":31791,"company_name":"REVVITY, INC.","ticker":"RVTY","form_type":"8-K","filed_at":"2026-01-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Revvity pre-announces Q4 2025 revenue ~$772M, adj. EPS above guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 revenue expected ~$772M, reported +6% and organic +4% YoY.","Full year 2025 revenue expected ~$2,855M, reported +4% and organic +3% YoY.","Full year adjusted EPS expected to exceed prior guidance range of $4.90-$5.00.","Q4 earnings call scheduled for Feb 2, 2026 at 8:00 AM ET.","CEO to present at J.P. Morgan Healthcare Conference on Jan 13, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":2.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":2856051000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":10797870952.86337,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":129559,"accession_number":"0000031791-25-000032","cik":31791,"company_name":"REVVITY, INC.","ticker":"RVTY","form_type":"8-K","filed_at":"2025-10-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Revvity Q3: revenue $699M (+2%), GAAP EPS $0.40, adjusted EPS $1.18; raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $699M, up 2% reported / 1% organic; GAAP EPS $0.40 vs $0.77 a year ago.","Adjusted EPS from continuing ops $1.18 vs $1.28; adjusted operating profit margin 26.1% vs 28.3%.","GAAP operating income $82M (11.7% margin) down from $98M (14.3%) in prior-year quarter.","Reaffirms full-year 2025 organic growth; raises adjusted EPS guidance.","Board authorized new $1B share repurchase program."],"consensus_eps_estimate":null,"consensus_eps_actual":1.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":2083995000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":10797870952.86337,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":129558,"accession_number":"0001193125-25-249958","cik":31791,"company_name":"REVVITY, INC.","ticker":"RVTY","form_type":"8-K","filed_at":"2025-10-24T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Revvity appoints Anita Gonzales as Vice President and Chief Accounting Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Anita Gonzales appointed as Vice President and Chief Accounting Officer, effective Oct. 23, 2025.","Gonzales served as VP and Controller since May 2023, joined Revvity in March 2021.","Prior roles include GE Director of Audit (2016-2021) and PwC Senior Manager.","She holds a CPA and degrees from the University of Texas at Austin."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":10797870952.86337,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":146130,"accession_number":"0000031791-25-000022","cik":31791,"company_name":"REVVITY, INC.","ticker":"RVTY","form_type":"8-K","filed_at":"2025-07-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Revvity Q2 revenue $720M (+4% reported), GAAP EPS $0.46, adjusted EPS $1.18; updates FY2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Revenue $720M, +4% reported and +3% organic; GAAP EPS $0.46 vs $0.45 prior year.","Adjusted EPS $1.18 vs $1.22 YoY; adjusted operating margin 26.6% vs 28.8%.","GAAP operating income $91M, up from $86M; adjusted operating income $192M vs $199M.","Full year 2025 guidance updated; specifics not provided in excerpt."],"consensus_eps_estimate":null,"consensus_eps_actual":0.81,"consensus_revenue_estimate":null,"consensus_revenue_actual":1385046000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":10797870952.86337,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":164442,"accession_number":"0000031791-25-000012","cik":31791,"company_name":"REVVITY, INC.","ticker":"RVTY","form_type":"8-K","filed_at":"2025-04-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Revvity Q1 revenue $665M (+4% organic), GAAP EPS $0.35, adjusted EPS $1.01; reaffirms FY2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $665M, up 2% reported and 4% organic YoY.","GAAP EPS $0.35 vs $0.21 YoY; adjusted EPS $1.01 vs $0.98.","GAAP operating margin 10.9% (6.8% YoY); adjusted margin 25.6% (25.5% YoY).","Full year 2025 organic growth and adjusted EPS guidance reaffirmed."],"consensus_eps_estimate":null,"consensus_eps_actual":0.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":664762000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":10797870952.86337,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":164441,"accession_number":"0001193125-25-096747","cik":31791,"company_name":"REVVITY, INC.","ticker":"RVTY","form_type":"8-K","filed_at":"2025-04-25T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Shareholders approve majority voting standard and special meeting proposal at Revvity annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders elected all 10 director nominees with over 96% support; no contested election.","Majority voting standard proposal approved with 98.4M for, 0.36M against (excl. broker non-votes).","Shareholder proposal to allow special meetings passed with 66.9M for vs 35.3M against.","Executive compensation non-binding advisory vote passed with 92.8M for (91.5% of votes cast).","Ratification of Deloitte as auditor approved with 103.6M for (98.0% of votes cast)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":10797870952.86337,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":182202,"accession_number":"0000031791-25-000006","cik":31791,"company_name":"REVVITY, INC.","ticker":"RVTY","form_type":"8-K","filed_at":"2025-01-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Revvity Q4 revenue $729M (+6% organic), adj EPS $1.42; FY adj EPS $4.90","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Q4 revenue $729M (+5% reported, +6% organic); GAAP EPS $0.78 (vs $0.64); adjusted EPS $1.42 (vs $1.25).","Full year 2024 revenue $2,755M (flat YoY); GAAP EPS $2.20 (down from $5.55); adjusted EPS $4.90 (up from $4.65).","Q4 adjusted operating margin 30.3% (vs 27.5%); full year adjusted margin 28.3% (vs 28.0%).","Company initiates full year 2025 guidance; specific numbers not included in the press release excerpt."],"consensus_eps_estimate":null,"consensus_eps_actual":2.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":2755026000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":10797870952.86337,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":182201,"accession_number":"0000031791-25-000003","cik":31791,"company_name":"REVVITY, INC.","ticker":"RVTY","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Revvity provides preliminary Q4 revenue ~$730M, 6% organic growth; EPS guidance reaffirmed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 preliminary revenue ~$730M; reported growth ~5%, organic ~6% vs. prior year.","Full-year 2024 adjusted EPS expected to meet or exceed guidance provided Nov 4, 2024.","Q4 and full-year 2024 results to be released Jan 31, 2025; conference call at 8am ET.","CEO Prahlad Singh to present at J.P. Morgan Healthcare Conference on Jan 13, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":2.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":2755026000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":10797870952.86337,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":182200,"accession_number":"0001193125-25-002871","cik":31791,"company_name":"REVVITY, INC.","ticker":"RVTY","form_type":"8-K","filed_at":"2025-01-07T23:59:59+00:00","items":["1.01","1.02","2.03","9.01"],"status":"ready","headline":"Revvity enters new $1.5B revolving credit facility maturing 2030, replaces prior facility","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["New $1.5B unsecured revolver matures Jan 7, 2030; replaces prior $1.5B facility due Aug 2026.","No borrowings outstanding at closing; only $4.2M in letters of credit outstanding.","Interest rate based on debt ratings: term SOFR + spread 0.795%-1.425%; facility fee 0.08%-0.20%.","Joint lead arrangers: BofA Securities, JPMorgan, Goldman Sachs, PNC Capital Markets, Wells Fargo."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":10797870952.86337,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":198829,"accession_number":"0000031791-24-000026","cik":31791,"company_name":"REVVITY, INC.","ticker":"RVTY","form_type":"8-K","filed_at":"2024-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Revvity Q3 GAAP EPS $0.77, adj. EPS $1.28; raises FY guidance; $1B buyback","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $684M, +2% reported and organic YoY; GAAP operating margin 14.3% vs 10.3%.","GAAP EPS $0.77 vs $0.08 a year ago; adjusted EPS from continuing ops $1.28 vs $1.18.","Adjusted operating margin 28.3% vs 27.5%; adjusted operating income $193M.","Raises full-year 2024 adjusted EPS guidance (specific figures not disclosed in release).","Board authorizes new $1B share repurchase program; investor day set for Nov 21, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":1.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":2025654000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":10797870952.86337,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":214870,"accession_number":"0000031791-24-000018","cik":31791,"company_name":"REVVITY, INC.","ticker":"RVTY","form_type":"8-K","filed_at":"2024-07-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Revvity Q2 2024: GAAP EPS $0.45, Adj EPS $1.22; raises full-year adj EPS guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $692M (-2% reported, -1% organic); GAAP EPS $0.45 vs $0.28 YoY.","Adjusted EPS $1.22 vs $1.21 YoY; adj operating margin 28.7% (vs 28.8%).","Raises full-year 2024 adjusted EPS guidance (no numeric range disclosed).","GAAP operating income $86M (12.4% margin) vs $78M (11.0%) YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":0.66,"consensus_revenue_estimate":null,"consensus_revenue_actual":1341605000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":10797870952.86337,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":234044,"accession_number":"0001628280-24-018795","cik":31791,"company_name":"REVVITY, INC.","ticker":"RVTY","form_type":"8-K","filed_at":"2024-04-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Revvity Q1 revenue down 4% to $650M; GAAP EPS $0.21 vs $4.50; reaffirms FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $650M, -4% reported, -3% organic; GAAP EPS $0.21 vs $4.50 (prior year included large gain from discontinued ops).","Adjusted EPS from continuing ops $0.98 vs $1.01; adjusted operating margin 25.5% vs 28.0%.","GAAP operating income $44M, margin 6.8%; adjusted operating income $166M, margin 25.5%.","Reaffirmed full-year 2024 organic growth and adjusted EPS guidance."],"consensus_eps_estimate":null,"consensus_eps_actual":0.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":649920000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":10797870952.86337,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":234043,"accession_number":"0001193125-24-110060","cik":31791,"company_name":"REVVITY, INC.","ticker":"RVTY","form_type":"8-K","filed_at":"2024-04-24T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Revvity annual meeting approves all proposals, including director elections and say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 10 director nominees elected with majority support; Chapin received most votes (101.9M), Witney fewest (98.7M).","Ratification of Deloitte & Touche as auditor passed: 100.4M for, 6.7M against.","Advisory vote on executive compensation approved: 98.0M for, 4.4M against, 4.4M broker non-votes.","Shareholder proposal to adopt simple majority voting standard passed: 98.7M for, 3.4M against.","Meeting held April 23, 2024; results reflect routine governance matters with no unexpected outcomes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":10797870952.86337,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":251996,"accession_number":"0001157523-24-000146","cik":31791,"company_name":"REVVITY, INC.","ticker":"RVTY","form_type":"8-K","filed_at":"2024-02-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Revvity Q4 revenue $696M (-6%), adjusted EPS $1.25 vs $1.41; full year adjusted EPS $4.65 vs $6.92","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 GAAP EPS $0.64 vs $1.01; adjusted EPS $1.25 vs $1.41; revenue down 6% reported, 7% organic.","Full year 2023 GAAP EPS $5.55 vs $4.50; adjusted EPS $4.65 vs $6.92; revenue $2,751M (-17%).","Q4 GAAP operating margin 11.1% (vs 18.5%); adjusted operating margin 27.5% (vs 32.3%).","Full year adjusted operating margin 28.0% vs 36.6% in 2022; non-COVID organic revenue -3% in Q4.","Company initiates full year 2024 guidance; specific numbers not disclosed in this excerpt."],"consensus_eps_estimate":null,"consensus_eps_actual":5.55,"consensus_revenue_estimate":null,"consensus_revenue_actual":2750571000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":10797870952.86337,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":251995,"accession_number":"0001157523-24-000120","cik":31791,"company_name":"REVVITY, INC.","ticker":"RVTY","form_type":"8-K","filed_at":"2024-01-26T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Revvity elects two new directors; Dr. Sylvie Grégoire not seeking re-election","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Sylvie Grégoire not standing for re-election at the 2024 annual meeting on Apr 23; no disagreement with company.","Board elected Michael A. Klobuchar and Sophie V. Vandebroek as directors, effective Feb 1, 2024.","New directors receive prorated annual equity ($22,500 stock + $27,500 RSU) and prorated cash retainer of $90,000.","Neither Klobuchar nor Vandebroek will initially serve on a board committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":10797870952.86337,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":251994,"accession_number":"0001157523-24-000035","cik":31791,"company_name":"REVVITY, INC.","ticker":"RVTY","form_type":"8-K","filed_at":"2024-01-09T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Revvity issues preliminary Q4 2023 revenue at least $690M with organic decline of 4-7%, EPS guidance reaffirmed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 revenue expected at least $690M, reported organic revenue decline of approx. 7% and non-COVID organic decline of 4% year-over-year.","Full-year 2023 adjusted EPS expected to meet or exceed the guidance provided on October 30, 2023.","Company will release Q4 and full-year 2023 results on February 1, 2024, with a conference call at 8:00 a.m. ET hosted by CEO Prahlad Singh.","CEO Prahlad Singh presented at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":5.55,"consensus_revenue_estimate":null,"consensus_revenue_actual":2750571000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":10797870952.86337,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":269530,"accession_number":"0001157523-23-001568","cik":31791,"company_name":"REVVITY, INC.","ticker":"RVTY","form_type":"8-K","filed_at":"2023-10-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Revvity Q3 revenue $671M, -7% organic; adj EPS $1.18; updates FY23 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP EPS $0.08 vs $0.67 a year ago; GAAP revenue $671M (-6% reported, -7% organic).","Non-COVID organic revenue grew 1% in Q3; adjusted EPS $1.18 vs $1.21 prior year.","GAAP operating margin 10.3% vs 15.6% YoY; adjusted operating margin 27.5% vs 31.4%.","Full year 2023 guidance updated; specific new ranges not disclosed in filing."],"consensus_eps_estimate":null,"consensus_eps_actual":4.9,"consensus_revenue_estimate":null,"consensus_revenue_actual":2054670000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":10797870952.86337,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":286506,"accession_number":"0001157523-23-001197","cik":31791,"company_name":"REVVITY, INC.","ticker":"RVTY","form_type":"8-K","filed_at":"2023-08-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Revvity Q2 revenue $709M, down 21%; GAAP EPS $0.28, adjusted EPS $1.21","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Revenue $709M, down 21% reported and 20% organic; non-COVID organic growth of 6%.","GAAP EPS $0.28 vs $1.42 prior year; adjusted EPS $1.21 vs $1.98.","GAAP operating margin 11.0% vs 26.0%; adjusted operating margin 28.8% vs 39.6%.","Full-year 2023 guidance updated; specific numbers not provided in the excerpt."],"consensus_eps_estimate":null,"consensus_eps_actual":4.8,"consensus_revenue_estimate":null,"consensus_revenue_actual":1383931000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":10797870952.86337,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":306413,"accession_number":"0001157523-23-000815","cik":31791,"company_name":"REVVITY, INC.","ticker":"RVTY","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Revvity Q1 revenue $675M (-30% reported); GAAP EPS $4.50, adjusted EPS $1.01; $600M buyback authorized","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $675M, down 30% reported (-27% organic); non-COVID organic growth 6%.","GAAP EPS $4.50 (includes non-recurring items); adjusted EPS from continuing ops $1.01 vs $2.30 YoY.","Adjusted operating margin 28.0% vs 40.8% YoY; adjusted operating income $189M.","Authorized new $600M share repurchase program; ticker to change to RVTY on May 16, 2023.","Full-year 2023 guidance updated (specifics not in excerpt)."],"consensus_eps_estimate":null,"consensus_eps_actual":4.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":674865000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":10797870952.86337,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":306412,"accession_number":"0001193125-23-126948","cik":31791,"company_name":"REVVITY, INC.","ticker":"RVTY","form_type":"8-K","filed_at":"2023-04-28T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"PerkinElmer shareholders approve name change to Revvity, effective April 26, 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Name change from PerkinElmer to Revvity approved with 111M votes in favor, 801K against.","Bylaws amended to reflect new name; restated articles filed as Exhibit 3.1.","All nine director nominees elected, including Peter Barrett, Samuel Chapin, Sylvie Grégoire.","Deloitte & Touche ratified as independent auditor for fiscal year.","Advisory vote on executive compensation approved; company to hold annual say-on-pay votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":10797870952.86337,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":325553,"accession_number":"0001193125-23-071549","cik":31791,"company_name":"REVVITY, INC.","ticker":"RVTY","form_type":"8-K","filed_at":"2023-03-16T23:59:59+00:00","items":["1.01","2.01","9.01"],"status":"ready","headline":"PerkinElmer closes sale of Applied, Food and Enterprise Services businesses for ~$2.136B to New Mountain Capital","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Sale of Business (Applied, Food, Enterprise Services) closed Mar 13, 2023; cash consideration ~$2.136B, subject to adjustments.","Amended agreement modifies internal reorganization, IT separation, and defers transfer of operations in UK, Singapore, Thailand, Argentina.","$75M deferred payment for brand/trademark tied to PKI's election; buyer receives upon transfer.","Buyer is PerkinElmer Topco, L.P., owned by New Mountain Capital funds."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":10797870952.86337,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":325552,"accession_number":"0001157523-23-000272","cik":31791,"company_name":"REVVITY, INC.","ticker":"RVTY","form_type":"8-K","filed_at":"2023-02-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PerkinElmer Q4 revenue $741M; GAAP EPS $0.85; combined adjusted EPS $1.70; initiates 2023 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 GAAP revenue from continuing ops $741M, down 28% reported; 8% non-COVID organic growth.","Q4 GAAP EPS from continuing ops $0.85 vs $1.45; combined adjusted EPS $1.70 vs $2.56.","Full year 2022: GAAP EPS from continuing ops $4.13 vs $7.62; combined adjusted EPS $7.95 vs $11.36.","Combined adjusted revenue FY2022 $4.61B, down from $5.07B; combined adjusted operating margin 30.0%.","Company initiated FY2023 guidance; specific numbers not provided in excerpt."],"consensus_eps_estimate":null,"consensus_eps_actual":4.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":3311822000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":10797870952.86337,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":325551,"accession_number":"0001157523-23-000033","cik":31791,"company_name":"REVVITY, INC.","ticker":"RVTY","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PerkinElmer expects Q4 2022 results to meet or exceed prior guidance; earnings call Feb 14","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2022 results expected to meet or exceed guidance provided on Nov 8, 2022.","Earnings call to discuss Q4 and FY 2022 results scheduled for Feb 14, 2023 at 8:00 a.m. ET.","CEO Prahlad Singh and CFO Max Krakowiak to host the conference call."],"consensus_eps_estimate":null,"consensus_eps_actual":4.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":3311822000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":10797870952.86337,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":343293,"accession_number":"0001157523-22-001552","cik":31791,"company_name":"REVVITY, INC.","ticker":"RVTY","form_type":"8-K","filed_at":"2022-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PerkinElmer Q3 revenue $712M (-17% reported); pro forma adj EPS $1.51","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP revenue $712M (down 17% YoY); GAAP EPS from continuing ops $0.55 vs $0.94.","Pro forma total revenue $1,033M; 9% pro forma non-COVID organic growth.","Pro forma adj EPS $1.51 vs $2.31 in prior-year quarter.","GAAP operating margin 15.6%, adj 31.4%, pro forma adj margin 26.3%.","Company initiates Q4 2022 guidance and updates full-year pro forma outlook."],"consensus_eps_estimate":null,"consensus_eps_actual":3.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":711803000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":10797870952.86337,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":343292,"accession_number":"0001157523-22-001320","cik":31791,"company_name":"REVVITY, INC.","ticker":"RVTY","form_type":"8-K","filed_at":"2022-10-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PerkinElmer sees Q3 organic revenue growth and adjusted EPS above prior guidance","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Preliminary Q3 2022: organic revenue growth and adjusted EPS expected to exceed prior guidance.","Total revenue near high-end of prior range due to larger-than-expected FX headwinds.","Full Q3 results to be released Nov 8, 2022; webcast at 8:00 a.m. ET.","Non-COVID organic revenue growth also anticipated above prior guidance."],"consensus_eps_estimate":null,"consensus_eps_actual":3.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":711803000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":10797870952.86337,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":359845,"accession_number":"0001193125-22-222840","cik":31791,"company_name":"REVVITY, INC.","ticker":"RVTY","form_type":"8-K","filed_at":"2022-08-17T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CFO James Mock resigns; Maxwell Krakowiak named new CFO effective Sep 6, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["James M. Mock resigns as CFO and terminates employment on Sep 5, 2022.","Maxwell Krakowiak appointed SVP & CFO effective Sep 6, 2022; internal promotion since Oct 2018.","Krakowiak receives $500K base salary, target bonus 75% of salary, LTIP grant of 225% of salary.","Sign-on equity grant of $500K split between stock options and restricted stock.","Employment agreement includes one-year non-compete and severance/change-in-control provisions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":10797870952.86337,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":359844,"accession_number":"0001193125-22-213623","cik":31791,"company_name":"REVVITY, INC.","ticker":"RVTY","form_type":"8-K","filed_at":"2022-08-05T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"PerkinElmer sells Applied, Food & Enterprise Services to New Mountain Capital for up to $2.45B","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Cash consideration up to ~$2.45B; ~$2.3B at closing including $75M deferred for brand transfer.","Buyer is Polaris Purchaser, L.P., owned by funds managed by New Mountain Capital.","Closing expected no earlier than Dec 1, 2022; subject to HSR, foreign approvals, and reorganization.","Buyer pays $75M reverse termination fee if terminated under certain conditions; financing not a condition.","Three-year non-compete for PerkinElmer in the sold businesses after closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":10797870952.86337,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":359843,"accession_number":"0001157523-22-000967","cik":31791,"company_name":"REVVITY, INC.","ticker":"RVTY","form_type":"8-K","filed_at":"2022-08-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PerkinElmer Reports Q2 2022 Results and Plans to Divest Applied, Food, and Enterprise Services","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Second quarter revenue was $1.23 billion with 0% reported growth and 8% non-COVID organic growth.","GAAP EPS from continuing operations was $1.42; adjusted EPS was $2.32.","Signed agreement to divest Applied, Food, and Enterprise Services businesses.","Raised full year guidance and initiated third quarter guidance.","Earnings call moved to 8:00 a.m. ET on August 1, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":2.81,"consensus_revenue_estimate":null,"consensus_revenue_actual":895642000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":10797870952.86337,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":359842,"accession_number":"0001193125-22-200030","cik":31791,"company_name":"REVVITY, INC.","ticker":"RVTY","form_type":"8-K","filed_at":"2022-07-22T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"PerkinElmer elects Dr. Michelle McMurry-Heath to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. McMurry-Heath elected to the Board effective July 22, 2022.","Receives stock award of $91,667 and RSUs of $75,000, prorated annual equity.","Eligible for annual cash retainer of $90,000 for non-employee directors, prorated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":10797870952.86337,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":378706,"accession_number":"0001157523-22-000546","cik":31791,"company_name":"REVVITY, INC.","ticker":"RVTY","form_type":"8-K","filed_at":"2022-05-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PerkinElmer Q1 revenue $1.26B; GAAP EPS $1.40, adjusted EPS $2.41; all down YoY; raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1.26B, down 3.8% YoY from $1.31B.","GAAP EPS $1.40 (down 58% YoY); adjusted EPS $2.41 (down 35% YoY).","GAAP operating margin 20.2% vs 35.8% YoY; adjusted operating margin 32.5% vs 41.4% YoY.","Initiates Q2 guidance and raises full-year FY2022 guidance (specifics not provided in filing)."],"consensus_eps_estimate":null,"consensus_eps_actual":1.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":963163000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":10797870952.86337,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":378705,"accession_number":"0001193125-22-133586","cik":31791,"company_name":"REVVITY, INC.","ticker":"RVTY","form_type":"8-K","filed_at":"2022-04-29T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"PerkinElmer shareholders elect all director nominees, ratify auditor, approve exec comp at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All eight director nominees elected; Alexis P. Michas received 82.4M for (79.1%) and 22.0M against.","Deloitte & Touche ratified with 108.5M for (98.3%) vs 1.7M against.","Advisory executive compensation approved with 99.2M for, 5.1M against (95.1% support).","Broker non-votes of 5.86M shares on director elections and compensation proposal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":10797870952.86337,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":378704,"accession_number":"0001193125-22-093609","cik":31791,"company_name":"REVVITY, INC.","ticker":"RVTY","form_type":"8-K","filed_at":"2022-04-01T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"PerkinElmer receives notice CDPH to end Valencia Lab contract on May 15, 2022; reaffirms $400M+ COVID revenue in 2022","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CDPH to end contract for supply and operation of Valencia Branch Laboratory effective May 15, 2022 due to decrease in COVID cases.","Company reiterates expectation of at least $400 million aggregate COVID-related revenue in 2022.","Further update to be provided on Q1 2022 earnings call."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":10797870952.86337,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":396959,"accession_number":"0001157523-22-000130","cik":31791,"company_name":"REVVITY, INC.","ticker":"RVTY","form_type":"8-K","filed_at":"2022-02-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PerkinElmer Q4 GAAP EPS $1.41 vs $3.38 YoY; revenue flat at $1.36B; organic growth -9%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2021 revenue $1.36B, 1% reported growth, -9% organic growth year-over-year.","GAAP EPS from continuing ops $1.41 (Q4 2021) vs $3.38 (Q4 2020); adjusted EPS $2.56 vs $3.96.","Full year 2021 GAAP EPS $7.99 vs $6.50; adjusted EPS $11.36 vs $8.30; revenue $5.067B vs $3.783B.","Company initiated Q1 and full year 2022 guidance (specific numbers not in excerpt).","GAAP operating margin 22.7% Q4 2021 vs 37.7% Q4 2020; adjusted margin 33.6% vs 42.2%."],"consensus_eps_estimate":null,"consensus_eps_actual":8.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":3827808000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":10797870952.86337,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":396958,"accession_number":"0001157523-22-000044","cik":31791,"company_name":"REVVITY, INC.","ticker":"RVTY","form_type":"8-K","filed_at":"2022-01-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PerkinElmer raises Q4 2021 outlook: adj. EPS at least $2.40, non-COVID organic growth ~10%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2021 adjusted EPS expected at least $2.40, above prior guidance.","Q4 non-COVID organic growth ~10%; full-year 2021 non-COVID organic growth ~16%.","Q4 COVID-related revenue ~$320M; full-year COVID revenue over $1.5B.","Full-year 2021 total revenue ~$5.0B: Diagnostics ~$2.9B, Discovery & Analytical Solutions ~$2.1B."],"consensus_eps_estimate":null,"consensus_eps_actual":8.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":3827808000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":10797870952.86337,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":415913,"accession_number":"0001193125-21-320153","cik":31791,"company_name":"REVVITY, INC.","ticker":"RVTY","form_type":"8-K/A","filed_at":"2021-11-04T23:59:59+00:00","items":["2.01","9.01"],"status":"ready","headline":"BioLegend FY2020 audited: revenue $241.9M, net income $90.6M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["BioLegend net sales $241.9M, gross profit $169.7M, operating income $109.6M, net income $90.2M.","Total assets $465.9M at Dec 31, 2020; cash $134.4M, short-term investments $90.0M.","Pro forma combined financials for PerkinElmer and BioLegend for FY2020 and H1 2021 filed.","Acquisition completed Sept 17, 2021 via merger of wholly owned subsidiaries."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":10797870952.86337,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":415915,"accession_number":"0001157523-21-001307","cik":31791,"company_name":"REVVITY, INC.","ticker":"RVTY","form_type":"8-K","filed_at":"2021-11-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PerkinElmer Q3 revenue $1.17B (+21%) adj EPS $2.31 beats; raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1.17B, up 21% reported, 12% organic; GAAP EPS $1.11, adj EPS $2.31.","GAAP operating margin 19.0% (down from 25.7%); adj operating margin 30.8% (down from 31.6%).","Initiates Q4 guidance and raises full-year revenue and earnings outlook.","Reported GAAP operating income $222M vs $248M YoY; adjusted operating income $359M vs $304M."],"consensus_eps_estimate":null,"consensus_eps_actual":6.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":861315000.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":10797870952.86337,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":415914,"accession_number":"0001193125-21-289807","cik":31791,"company_name":"REVVITY, INC.","ticker":"RVTY","form_type":"8-K","filed_at":"2021-10-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"PerkinElmer files 8-K to incorporate legal opinion into shelf registration","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filed on October 1, 2021, to incorporate by reference into Form S-3 (File No. 333-230425).","Includes opinion of Wilmer Cutler Pickering Hale and Dorr LLP as Exhibit 5.1.","Includes consent of Wilmer Cutler Pickering Hale and Dorr LLP as Exhibit 23.1.","Signed by Vice President and Associate General Counsel John L. Healy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":10797870952.86337,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":433537,"accession_number":"0001193125-21-277478","cik":31791,"company_name":"REVVITY, INC.","ticker":"RVTY","form_type":"8-K","filed_at":"2021-09-21T23:59:59+00:00","items":["2.01","1.01","2.03","3.02","9.01"],"status":"ready","headline":"PerkinElmer closes $5.25B BioLegend acquisition; issues ~14.1M shares as stock consideration","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Aggregate purchase price ~$5.25B; paid 59.5% cash and 40.5% stock valued at $156.3561/share.","Cash funded by $2.28B notes offering, $500M term loan draw, ~$300M revolver draw, and cash on hand.","Transaction closed on September 17, 2021; previously announced on July 25, 2021.","Issued 14,066,771 shares of common stock in a private placement to BioLegend stockholders.","Financial statements and pro forma information to be filed by amendment within 71 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":10797870952.86337,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":433536,"accession_number":"0001193125-21-269959","cik":31791,"company_name":"REVVITY, INC.","ticker":"RVTY","form_type":"8-K","filed_at":"2021-09-10T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"PerkinElmer issues $2.3B in senior notes to finance BioLegend acquisition","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $2.3B aggregate: $500M 0.55% notes due 2023, $800M 0.85% due 2024, $500M 1.90% due 2028, $500M 2.25% due 2031.","Net proceeds ~$2.28B to partially fund $5.7B BioLegend acquisition announced July 25, 2021.","Special mandatory redemption at 101% if BioLegend deal not closed by Jan 31, 2022.","Bridge loan commitments reduced to $514M after net proceeds.","Notes are general unsecured, rank equally with other unsecured debt."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":10797870952.86337,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":433535,"accession_number":"0001193125-21-256291","cik":31791,"company_name":"REVVITY, INC.","ticker":"RVTY","form_type":"8-K","filed_at":"2021-08-25T23:59:59+00:00","items":["1.01","1.02","2.03","9.01"],"status":"ready","headline":"PerkinElmer enters $1.5B revolving credit facility, replacing $1B prior facility, maturing 2026","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$1.5B unsecured revolving credit facility, available through August 24, 2026; replaces prior $1B facility dated September 2019.","Initial borrowings of $60M and €90M plus $10.9M in letters of credit outstanding at closing.","Interest rate at base rate or eurocurrency rate plus spread (0.795%-1.425% for eurocurrency) based on credit ratings; facility fee 0.08%-0.20%.","Proceeds for working capital, capital expenditures, acquisitions, share repurchases, dividends, and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":10797870952.86337,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":433534,"accession_number":"0001193125-21-244659","cik":31791,"company_name":"REVVITY, INC.","ticker":"RVTY","form_type":"8-K","filed_at":"2021-08-12T23:59:59+00:00","items":["1.01","2.03","8.01","9.01"],"status":"ready","headline":"PerkinElmer enters $500M delayed draw term loan to partly fund BioLegend acquisition","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Unsecured term loan facility for $500M to fund portion of BioLegend acquisition, refinance BioLegend debt, and pay fees.","Loan available until earlier of consummation of BioLegend acquisition or five business days after Oct 25, 2021 (possible extension to Jan 31, 2022).","Matures on third anniversary of funding date; interest at base rate or eurocurrency rate plus spread based on debt rating.","Concurrent $500M reduction in existing 364-day senior unsecured bridge term loan facility from Goldman Sachs.","Covenants include debt-to-capitalization ratio (replaced by leverage/interest coverage if below investment grade) and customary events of default."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":10797870952.86337,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":433533,"accession_number":"0001193125-21-225700","cik":31791,"company_name":"REVVITY, INC.","ticker":"RVTY","form_type":"8-K","filed_at":"2021-07-27T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"PerkinElmer to acquire BioLegend for $5.25B; expects $0.30 adjusted EPS accretion in first full year","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Purchase price ~$5.25B; 59.5% cash and 40.5% stock at $156.3561/share.","BioLegend estimated 2022 revenues ~$380M with mid-teens-plus growth.","Expected $0.30 adjusted EPS accretion in 1st full year, >$0.50 in 2nd year.","Revenue synergies expected $100M annually by 5th year post-close; no significant cost synergies planned.","Bridge financing of $3.3B committed by Goldman Sachs; no financing condition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":10797870952.86337,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":433532,"accession_number":"0001157523-21-000916","cik":31791,"company_name":"REVVITY, INC.","ticker":"RVTY","form_type":"8-K","filed_at":"2021-07-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PerkinElmer Q2 revenue $1.228B (+51%); raises guidance; to acquire BioLegend","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1.228B, +51% reported, +41% organic; GAAP EPS $2.19, adjusted EPS $2.83.","Raises full-year revenue and earnings guidance; initiates Q3 guidance.","Agrees to acquire BioLegend, a leading antibody & research reagent provider.","GAAP operating margin 27.1% (vs 21.6% Q2 2020); adjusted margin 33.5% (vs 28.1%).","Earnings call moved to July 26 at 8:00 a.m. ET."],"consensus_eps_estimate":null,"consensus_eps_actual":5.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":910747000.0,"consensus_period":"2021-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":10797870952.86337,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}